NCT00444717

Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome

Multicenter Study for Anti-oxidative and Anti-inflammatory Effects of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Aichi Gakuin University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate anti-oxidative and anti-inflammatory effects of pitavastatin in hypercholesterolemic patients with the metabolic syndrome.

Detailed description

The metabolic syndrome is defined as a cluster of cardiovascular risk factors including visceral obesity, dyslipidemia, elevated blood pressure and impaired glucose tolerance. Recently, it has been described that oxidative stress and inflammatory reaction, which are important in progression of atherosclerosis, increases in individuals with the metabolic syndrome. Statins might have beneficial effects such as anti-oxidative and anti-inflammatory actions that are independent from their cholesterol-lowering effects. Pitavastatin, a chemically synthesized statin, has potent LDL-cholesterol lowering and also anti-oxidative and anti-inflammatory effects in animal studies. However, the effects of pitavastatin on oxidative stress and inflammatory action in patients with the metabolic syndrome have not been reported.

Conditions

• Metabolic Syndrome
• Oxidative Stress
• Inflammation

Interventions

Type	Name	Description
DRUG	pitavastatin	Pitavastatin (2mg/day) was administered for 12 weeks

Timeline

• Start date: 2007-04-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2007-03-08
• Last updated: 2011-07-13

Locations

1 site across 1 country: Japan